Biohaven Ltd (BHVN) Stock Analysis

Verdict: AVOID

Biohaven's $795M SK licensing deal validates its pipeline, but severe $610M annual cash burn and imminent dilution risk keep 90-day return probability constrained.

Investment score: 36/100

Analysis as of 2026-08-28

Is Biohaven Ltd stock worth reviewing? AI model thesis

The AI model evaluates Biohaven as an AVOID due to high cash burn (-$610.15M FCF) and balance sheet debt ($284.61M), despite recent pipeline out-licensing progress.

7-factor investment score

Valuation: 20/100 (weight 20%)
Financial Health: 15/100 (weight 15%)
Technical Momentum: 65/100 (weight 15%)
Earnings Quality: 35/100 (weight 15%)
Insider Sentiment: 50/100 (weight 10%)
Analyst Consensus: 55/100 (weight 10%)
Risk-Adjusted Return: 30/100 (weight 15%)

Biohaven Ltd opportunities and risks

What speaks for BHVN

$795M SK Biopharmaceuticals Out-Licensing Deal

What speaks against BHVN

Severe Free Cash Flow Burn and Dilution Risk

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
BHVN	n/a	0.0x	n/a	0.0%	0.0%	-21.1%
RARE	n/a	3.6x	n/a	83.1%	-81.8%	-18.9%
PGEN	n/a	29.9x	n/a	89.6%	-184.0%	-4.5%
PURR	n/a	552.4x	n/a	100.0%	-4899.7%	-0.9%
BCRX	n/a	2.7x	n/a	23.5%	-40.9%	14.2%
KOD	n/a	0.0x	n/a	0.0%	0.0%	-6.5%
Peer median	n/a	3.6x	n/a	83.1%	-81.8%	-4.5%

Frequently asked questions about Biohaven Ltd (BHVN)

Is BHVN stock a good investment?

The cached TradeMates AI model rates Biohaven Ltd as AVOID with an investment score of 36/100. The AI model evaluates Biohaven as an AVOID due to high cash burn (-$610.15M FCF) and balance sheet debt ($284.61M), despite recent pipeline out-licensing progress. This is algorithmic model output, not personal investment advice.

Is BHVN stock a buy?

The TradeMates model verdict for BHVN is AVOID with an investment score of 36/100. Treat this as a model signal to review, not a personal buy recommendation.